Table 2.
Age at time of diagnosis | All PETs |
Functional PETs |
Nonfunctional PETs |
||||||
Overall | Female | Male | Overall | Female | Male | Overall | Female | Male | |
15–19 | 0.1 | 0.1 | 0.2 | 0 | 0 | 0 | 0.1 | 0.1 | 0.2 |
20–29 | 0.4 | 0.5 | 0.3 | 0.1 | 0.1 | 0.1 | 0.3 | 0.4 | 0.2 |
30–39 | 1.1 | 1.1 | 1.1 | 0.2 | 0.2 | 0.1 | 0.9 | 0.9 | 1.0 |
40–49 | 2.5 | 2.3 | 2.7 | 0.2 | 0.2 | 0.2 | 2.3 | 2.1 | 2.4 |
50–59 | 4.4 | 3.8 | 5.0 | 0.4 | 0.4 | 0.5 | 3.9 | 3.4 | 4.5 |
60–69 | 6.5 | 5.2 | 8.1 | 0.5 | 0.5 | 0.4 | 6.1 | 4.7 | 7.6 |
70–79 | 7.6 | 5.6 | 10.3 | 0.7 | 0.5 | 0.9 | 6.9 | 5.1 | 9.4 |
80+ | 4.6 | 3.5 | 7.0 | 0.3 | 0.3 | 0.3 | 4.3 | 3.2 | 6.7 |
PETs, pancreatic endocrine tumors; SEER, Surveillance, Epidemiology, and End Results.